These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1279288)

  • 21. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men.
    Andersen P; Seljeflot I; Herzog A; Arnesen H; Hjermann I; Holme I
    J Cardiovasc Pharmacol; 1998 May; 31(5):677-83. PubMed ID: 9593066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Doxazosin in the treatment of light-to-moderate arterial hypertension in a non-comparative multicenter study].
    Pessina AC
    Clin Ter; 1995 Jan; 146(1):3-12. PubMed ID: 7705011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tonocardin in complex treatment of diabetes mellitus concurrent with hypertension].
    Balabolkin MI; Khasanova ER; Trukhina TV; Kreminskaia VM
    Ter Arkh; 2002; 74(12):38-41. PubMed ID: 12577838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled-release doxazosin as combination therapy in hypertension: the GATES study.
    Black HR; Keck M; Meredith P; Bullen K; Quinn S; Koren A
    J Clin Hypertens (Greenwich); 2006 Mar; 8(3):159-66; quiz 167-8. PubMed ID: 16522992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha-adrenoceptor blockade in patients with mild to moderate hypertension: long-term renal effects of doxazosin.
    Krusell LR; Christensen CK; Pedersen OL
    J Cardiovasc Pharmacol; 1992 Sep; 20(3):440-4. PubMed ID: 1279290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?
    Chapman N; Chen CY; Fujita T; Hobbs FD; Kim SJ; Staessen JA; Tanomsup S; Wang JG; Williams B
    J Hypertens; 2010 Sep; 28(9):1796-803. PubMed ID: 20543713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters.
    Zehetgruber M; Christ G; Gabriel H; Mundigler G; Beckmann R; Binder BR; Huber K
    Thromb Haemost; 1998 Feb; 79(2):378-82. PubMed ID: 9493594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow.
    Andersson PE; Lithell H
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):323-33. PubMed ID: 8722435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antihypertensive and metabolic effects of doxazosin in hypertensive patients with concomitant non-insulin-dependent diabetes mellitus.
    Inoue Y; Kaku K; Kaneko T; Matsumura S; Nakayama H; Yoshizaki Y; Ando S; Inoue M; Hatao M
    J Int Med Res; 1996; 24(1):138-46. PubMed ID: 8674792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antihypertensive effects of doxazosin: a clinical overview.
    Cox DA; Leader JP; Milson JA; Singleton W
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):83S-90S. PubMed ID: 2939872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined effect of a low fat diet and doxazosin on blood pressure control and blood lipids. Hunter Hypertension Research Group.
    J Hum Hypertens; 1994 Dec; 8(12):907-10. PubMed ID: 7884789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients with uncontrolled hypertension or concomitant hypertension and benign prostatic hyperplasia.
    Zusman R
    Clin Cardiol; 2004 Feb; 27(2):63-9. PubMed ID: 14979621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension].
    Widimský J
    Vnitr Lek; 2015 Dec; 61(12):1067-71. PubMed ID: 26806502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism.
    Inukai T; Inukai Y; Matsutomo R; Okumura K; Takanashi K; Takebayashi K; Tayama K; Aso Y; Takemura Y
    J Int Med Res; 2004; 32(2):206-13. PubMed ID: 15080025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension.
    Nash DT; Schonfeld G; Reeves RL; Black H; Weidler DJ
    Am J Cardiol; 1987 May; 59(14):87G-90G. PubMed ID: 2884859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orthostatic hypertension: home blood pressure monitoring for detection and assessment of treatment with doxazosin.
    Hoshide S; Parati G; Matsui Y; Shibazaki S; Eguchi K; Kario K
    Hypertens Res; 2012 Jan; 35(1):100-6. PubMed ID: 21918522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the effect of celiprolol and nifedipine on blood pressure and plasma lipids.
    van Hoof R; Desager JP; Harvengt C; Fagard R; Lijnen P; Peerenboom P; Staessen J; Thijs L; Van Mieghem W; Amery A
    J Cardiovasc Pharmacol; 1992 Aug; 20(2):268-73. PubMed ID: 1381018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
    Pool JL
    Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: the ASOCIA Study.
    de Alvaro F; Hernández-Presa MA;
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):271-6. PubMed ID: 16495766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.